查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585642

生技药品合约开发市场：按来源、类型、适应症、阶段、服务类型、最终用户 - 2025-2030 年全球预测

Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生技药品合约开发市场价值为65.4亿美元，预计到2024年将达到73亿美元，复合年增长率为11.79%，到2030年将达到142.8亿美元。

生技药品合约开发包括由专业公司提供的服务，协助生物技术和製药公司开发生物製药，包括单株抗体、疫苗、细胞疗法和基因疗法。由于与生物製药开发相关的复杂而严格的监管要求，该领域变得越来越必要。应用跨越细胞株开发、製程优化和放大生产等各个阶段，并涉及生物製药和生物技术等产业。慢性病盛行率的上升、生物技术的进步以及对个人化医疗日益增长的兴趣推动了市场对先进生物治疗的需求。关键的成长要素包括研发活动的活性化、政府对生技药品开发的大力资助以及生物加工的技术创新。新的商机在于采用一次性技术来提高製程效率并减少交叉污染，以及成本敏感市场对生物相似药不断增长的需求。

主要市场统计
基准年[2023] 65.4亿美元
预测年份 [2024] 73亿美元
预测年份 [2030] 142.8亿美元
复合年增长率（%） 11.79%

然而，这种情况并非没有挑战。生技药品开发的高成本、技术人员的有限以及严格的法律规范可能会阻碍市场扩张。此外，智慧财产权问题和放大过程的复杂性也是主要障碍。人工智慧和机器学习的整合等创新可以优化开发流程并缩短上市时间，为业务成长提供了一条充满希望​​的道路。此外，探索新的表现系统和提高生物过程效率将是研究和创新的重要领域。该市场的特点是竞争激烈且分散，主要企业专注于策略联盟、收购和投资，以加强其服务产品并扩大其全球业务。为了保持成长并捕捉市场格局中的新兴趋势，寻求利用市场机会的公司需要投资最尖端科技、培育合资企业并积极应对监管环境。

市场动态：快速发展的生技药品合约开发市场的关键市场洞察

合约生技药品开发市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 疫苗和生物相似药製造的需求增加
    • 政府鼓励生技药品活动的倡议
    • 利用生技药品CDO 提高业务效率并降低成本
  • 市场限制因素
    • 最终使用者和 CDO 之间的沟通问题
  • 市场机会
    • 生技药品开发系统的技术进步
    • 投资扩大新生技药品合约开发服务
  • 市场挑战
    • 对知识产权侵权的担忧

波特五力：驾驭生技药品合约开发市场的策略工具

波特的五力架构是了解生技药品合约开发市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生技药品合约开发市场的外部影响

外部宏观环境因素在塑造生技药品合约开发市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生技药品合约开发市场的竞争状况

生技药品合约开发市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生技药品合约开发市场供应商绩效评估

FPNV定位矩阵是评估生技药品合约开发市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製合约生技药品开发市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生技药品合约开发市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 疫苗和生物相似药生产的需求增加
      • 政府鼓励生技药品活动的倡议
      • 利用生物製剂 CDO 提高业务效率并降低成本
    • 抑制因素
      • 最终使用者和 CDO 之间的沟通问题
    • 机会
      • 生物製药开发系统的技术进步
      • 投资扩大新生技药品的合约开发服务
    • 任务
      • 对知识产权侵权的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生技药品合约开发市场：依来源分类

  • 哺乳动物的
  • 微生物

第七章生技药品合约开发市场：按类型

  • 分子治疗
  • 单株抗体
  • 重组蛋白
  • 疫苗

第八章生技药品合约开发市场：依疾病适应症

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 肿瘤学

第九章生技药品合约开发市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 临床前

第10章生技药品合约开发市场：依服务类型

  • 细胞株开发
    • 哺乳动物的
    • 微生物
  • 製程开发
    • 下游
      • 杂质、分离、鑑定
      • 药物分析
      • 理化表征
    • 上游
      • 哺乳动物的
      • 微生物

第十一章生技药品合约开发市场：依最终用户分类

  • 生物製药公司
  • 研究室

第十二章美洲生技药品合约开发市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太生技药品合约开发市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章欧洲、中东和非洲的生技药品合约开发市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JRS PHARMA GmbH & Co. KG
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.
Product Code: MRR-957C47F8FF75

The Biologics Contract Development Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.30 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 14.28 billion by 2030.

Biologics Contract Development encompasses services provided by specialized companies to assist biotechnology and pharmaceutical firms in the development of biological products, including monoclonal antibodies, vaccines, cell therapies, and gene therapies. This sector is increasingly necessary due to the complexity and stringent regulatory requirements associated with biologic drug development. Applications span across various stages, such as cell line development, process optimization, and scale-up production, catering to industries like biopharmaceuticals and biotechnology. The market is buoyed by the rising prevalence of chronic diseases, advancements in biotechnology, and an increasing focus on personalized medicine, driving the demand for sophisticated biologic therapies. Key growth factors include intensifying research and development activities, robust government funding for biologics development, and technological innovations in bioprocessing. Emerging opportunities lie in the adoption of single-use technologies, which enhance process efficiency and reduce cross-contamination, as well as escalating demand for biosimilars in cost-sensitive markets.

KEY MARKET STATISTICS
Base Year [2023] USD 6.54 billion
Estimated Year [2024] USD 7.30 billion
Forecast Year [2030] USD 14.28 billion
CAGR (%) 11.79%

However, the landscape is not without challenges. High costs associated with biologics development, limited availability of skilled personnel, and stringent regulatory frameworks can hinder market expansion. Moreover, intellectual property issues and the complexity of scale-up processes pose significant barriers. Innovations such as the integration of artificial intelligence and machine learning for optimizing development processes and reducing time-to-market present promising avenues for business growth. Additionally, exploring novel expression systems and enhancing bioprocess efficiency provide areas for significant research and innovation. The market is characterized by a competitive and fragmented nature, with key players focusing on strategic partnerships, acquisitions, and investments to enhance their service offerings and expand their global footprint. Companies aiming to capitalize on market opportunities should invest in cutting-edge technologies, foster collaborative ventures, and address regulatory challenges proactively to sustain growth and capture emerging trends in the biologics contract development landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development Market

The Biologics Contract Development Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for vaccine and biosimilar production
    • Government initiatives encouraging biologics activities
    • Improved operational efficiency and cost saving with biologics CDO
  • Market Restraints
    • Communication issues between end-user and CDO
  • Market Opportunities
    • Technological advancements in biologics development systems
    • Investments in new biologics contract development services expansion
  • Market Challenges
    • Concerns associated with breach of intellectual property

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development Market

A detailed market share analysis in the Biologics Contract Development Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development Market

A strategic analysis of the Biologics Contract Development Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Type, market is studied across Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
  • Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Preclinical.
  • Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
  • Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccine and biosimilar production
      • 5.1.1.2. Government initiatives encouraging biologics activities
      • 5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
    • 5.1.2. Restraints
      • 5.1.2.1. Communication issues between end-user and CDO
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in biologics development systems
      • 5.1.3.2. Investments in new biologics contract development services expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with breach of intellectual property
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Development Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Contract Development Market, by Type

  • 7.1. Introduction
  • 7.2. Molecular Therapy
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Proteins
  • 7.5. Vaccines

8. Biologics Contract Development Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Oncology

9. Biologics Contract Development Market, by Phase

  • 9.1. Introduction
  • 9.2. Phase I
  • 9.3. Phase II
  • 9.4. Phase III
  • 9.5. Preclinical

10. Biologics Contract Development Market, by Service Type

  • 10.1. Introduction
  • 10.2. Cell Line Development
    • 10.2.1. Mammalian
    • 10.2.2. Microbial
  • 10.3. Process Development
    • 10.3.1. Downstream
      • 10.3.1.1. Impurity, Isolation, & Identification
      • 10.3.1.2. Pharmaceutical Analysis
      • 10.3.1.3. Physicochemical Characterization
    • 10.3.2. Upstream
      • 10.3.2.1. Mammalian
      • 10.3.2.2. Microbial

11. Biologics Contract Development Market, by End-User

  • 11.1. Introduction
  • 11.2. Biopharmaceutical Companies
  • 11.3. Research Laboratories

12. Americas Biologics Contract Development Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Biologics Contract Development Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Contract Development Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Aenova Holding GmbH
  • 4. AGC Biologics GmbH
  • 5. Avid Bioservices, Inc.
  • 6. Binex Co. Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Emergent BioSolutions, Inc.
  • 11. Fujifilm Holdings Corporation
  • 12. Icon PLC
  • 13. JRS PHARMA GmbH & Co. KG
  • 14. JSR Life Sciences, LLC
  • 15. Lonza Group AG
  • 16. Parexel International Corporation
  • 17. ProBioGen AG
  • 18. Recipharm AB
  • 19. Rentschler Biopharma SE
  • 20. Samsung Biologics
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Toyobo Co., Ltd.
  • 24. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (US